Abstract 475P
Background
Lobectomy had long been the established gold standard curative surgery for early stage lung cancer. With emerging evidence on the non-inferior outcome of segmentectomy, we had been performing segmentectomy on selected stage 1 lung cancer patients in our institution since 2012. It is timely for us to review our experience with segmentectomy in this group of patients.
Methods
We reviewed all the patients in our institution who underwent curative lung resection in a mixed Asian population over a 12-year period between 2006 and 2017. Staging was based on AJCC TNM 6th edition for patients before 2010 and 7th edition for patients after 2010. Only patients with stage 1 lung cancer were included in our study.
Results
269 patients were included in our study. 39 patients (14.5%) underwent segmentectomy, 225 patients (83.6%) underwent lobectomy and 5 patients (1.9%) underwent pneumonectomy. None of the segmentectomy cases had any visceral pleura or lymph node involvement reported on final histology. There was no significant difference in the mean duration of follow up between patients who had segmentectomy (5.37 +/- 2.94 years) and those who had lobectomy and above (6.41 +/- 3.43 years) (p = 0.083). Segmentectomy was associated with a significantly lower recurrence rate (OR 0.19, 95% CI 0.05-0.75) and a 5-year disease free survival of 96.6% compared to 73.1% in lobectomy patients (p = 0.002). The time to recurrence was also longer in segmentectomy patients (mean 4.25 +/- 3.53 years vs 2.78 +/- 2.23 years) but this was not statistically significant (p = 0.371). There was no significance difference in the short term 30-day survival between patients who underwent segmentectomy and lobectomy and above. There was also no significant difference in survival at 1, 3 and 5 years between the 2 groups of patients.
Conclusions
Our study demonstrated good disease-free survival in patients who underwent segmentectomy with no significant differences in overall survival. It is likely that careful selection of patients will produce equally good outcome in segmentectomy patients and this can give us renewed confidence in moving forward with lung preservation surgery for patients with early stage lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract